CVS Health (NYSE:CVS – Get Free Report) had its target price upped by stock analysts at Morgan Stanley from $93.00 to $106.00 in a research note issued on Thursday,MarketScreener reports. The firm presently has an “overweight” rating on the pharmacy operator’s stock. Morgan Stanley’s target price would suggest a potential upside of 7.85% from the stock’s previous close.
A number of other equities analysts have also issued reports on the company. Leerink Partners reaffirmed an “outperform” rating and set a $98.00 price target on shares of CVS Health in a research note on Thursday, March 5th. Bank of America cut their target price on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research note on Tuesday, January 27th. Piper Sandler lowered their price objective on shares of CVS Health from $101.00 to $99.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 31st. TD Cowen increased their price target on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Wolfe Research lowered their target price on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $98.08.
View Our Latest Stock Report on CVS Health
CVS Health Stock Up 0.2%
CVS Health (NYSE:CVS – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the previous year, the company posted $2.25 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, analysts forecast that CVS Health will post 7.46 earnings per share for the current fiscal year.
Insider Activity at CVS Health
In other news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.
Institutional Trading of CVS Health
A number of large investors have recently bought and sold shares of CVS. Caitong International Asset Management Co. Ltd lifted its holdings in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the period. Swiss RE Ltd. acquired a new stake in shares of CVS Health during the 4th quarter worth about $26,000. Sankala Group LLC acquired a new position in CVS Health in the fourth quarter valued at about $28,000. Global Trust Asset Management LLC grew its stake in CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after buying an additional 300 shares during the last quarter. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of CVS Health during the fourth quarter worth approximately $28,000. 80.66% of the stock is currently owned by institutional investors.
CVS Health News Roundup
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: CVS Health received higher price targets from JPMorgan Chase ($111) and Sanford C. Bernstein ($106), signaling increased Wall Street confidence in the stock’s upside. Analyst Price Target Updates
- Positive Sentiment: Investors are still focused on CVS’s strong Q1 performance, with the company beating estimates on both EPS and revenue, which has helped support the share price. CVS Health Stock Hits a New 52-Week High After Posting Strong Q1 Results. Here’s Why It Can Still Go Even Higher
- Positive Sentiment: CVS Health and WGU launched a new online pre-pharmacy degree program, which could help build a stronger pharmacist pipeline and support long-term staffing needs. CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
- Positive Sentiment: CVS Health’s Rhode Island stores now accept WIC for infant formula at all locations in the state, a small but supportive consumer-access initiative. All Rhode Island CVS Pharmacy Locations Now Accept WIC for Infant Formula
- Neutral Sentiment: CVS also won an AI industry award and highlighted operational technology improvements, but this is more of a long-term execution story than an immediate stock catalyst. CVS Health Wins Gold in Enterprise AI
- Negative Sentiment: Omnicare, a CVS subsidiary, received court approval to sell its business to GenieRx in bankruptcy proceedings, which underscores ongoing restructuring pressure in parts of CVS’s portfolio. CVS unit Omnicare wins court approval for sale to GenieRx
About CVS Health
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Featured Stories
- Five stocks we like better than CVS Health
- eVTOL Investing: Ditch the Taxi, Buy the Blueprint
- How Berkshire’s New York Times Bet Looks Today
- Affirm’s Google Deal Aims for Your Wallet
- Airplane Maintenance Companies That Keep Flights Moving Are Ready to Soar
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
